Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement.
CSPC Pharmaceutical Group has disclosed unaudited first-quarter 2026 financial data for its Shenzhen-listed subsidiary, CSPC Innovation Pharmaceutical, prepared under China Accounting Standards. The company stressed that the figures relate only to the subsidiary, are unaudited and consolidated, and urged shareholders and potential investors to exercise caution when trading its securities.
For the three months ended 31 March 2026, CSPC Innovation’s revenue rose 40.82% year on year to RMB 664.6 million, while its net loss attributable to shareholders deepened to RMB 93.9 million and operating cash flow turned more negative. Despite largely stable total assets and a modest decline in shareholder equity, profitability metrics deteriorated, suggesting higher investment or cost pressures even as top-line growth accelerates, which may weigh on near-term returns for stakeholders.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company with operations spanning innovative drug research, development and manufacturing. Through subsidiaries such as CSPC Innovation Pharmaceutical Co., Ltd., it focuses on the Chinese market, including listings on the ChiNext Market of the Shenzhen Stock Exchange, and develops a portfolio of specialty and innovative medicines.
YTD Price Performance: 6.52%
Average Trading Volume: 105,300,194
Technical Sentiment Signal: Buy
Current Market Cap: HK$103.3B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.